2008
FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial
Kuo PH, Carlson KR, Christensen I, Girardi M, Heald PW. FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. Molecular Imaging And Biology 2008, 10: 306-314. PMID: 18665425, DOI: 10.1007/s11307-008-0161-4.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaFDG PET/CTPhase II trialParticular positron emission tomographyT-cell lymphomaII trialNodal diseaseInitial PET/CT scanPET/CT scansEarly clinical trialsEvaluation of responseHistone deacetylase inhibitorsAlters gene transcriptionPositron emission tomographyFDG uptakeCutaneous lesionsFDG-PETPrognostic valueFuture trialsClinical trialsConclusionFurther studiesCell lymphomaCT scanDeacetylase inhibitorsHDAC inhibitorsFDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma
Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma. Molecular Imaging And Biology 2008, 10: 74-81. PMID: 18196347, DOI: 10.1007/s11307-007-0127-y.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaPET/CTT-cell lymphomaFDG uptakeD-glucose positron emission tomography/FDG PET/CTPositron emission tomography/PET/CT scansComprehensive case seriesTomography (CT) of patientsMonitoring of responseMalignant adenopathyActive diseaseAdvanced diseaseCutaneous examinationVisceral diseaseVisceral involvementLymph nodesCase seriesCutaneous lesionsPhysical examinationThicker tumorsTomography/Physical examIndividual patients'Coral reef' psoriasis: a marker of resistance to topical treatment.
Feldman SR, Brown KL, Heald P. 'Coral reef' psoriasis: a marker of resistance to topical treatment. The Journal Of Dermatological Treatment 2008, 19: 257-8. PMID: 18608734, DOI: 10.1080/09546630802032611.Peer-Reviewed Original Research
2007
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo M, Sterry W, Laroche L, Trautinger F, Whittaker S, for the ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110: 1713-1722. PMID: 17540844, DOI: 10.1182/blood-2007-03-055749.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaSézary syndromeMycosis fungoidesCutaneous lymphomasCutaneous Lymphoma Task ForceT-cell lymphomaPotential prognostic significanceStandardized clinical trialsClinical characteristicsStaging procedurePrognostic significanceTreatment of cancerStaging systemTumor cell biologyClinical trialsEuropean OrganizationLymphomaOriginal guidelinesFungoidesSyndromeInternational SocietyDiagnostic techniquesTask ForceEORTCPrognosis
1993
Cutaneous Cryptococcosis in a Patient with Cutaneous T Cell Lymphoma Receiving Therapy with Photopheresis and Methotrexate
Frieden T, Bia F, Heald P, Eisen R, Patterson T, Edelson R. Cutaneous Cryptococcosis in a Patient with Cutaneous T Cell Lymphoma Receiving Therapy with Photopheresis and Methotrexate. Clinical Infectious Diseases 1993, 17: 776-778. PMID: 8268362, DOI: 10.1093/clinids/17.4.776.Peer-Reviewed Original Research